Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback